Target overview
Synonyms
B7-H3|CD276
Emerging Competitive
B7-H3 / CD276
B7-H3 / CD276 is flagged as emerging competitive based on 18 active trials across 12 sponsors and 1 patent-density signals in public data. This is a public-data screen, not a legal, clinical, or investment conclusion.
Clinical activity
Public trial footprint
Clinical trials: 20
Active trials: 18
Recruiting trials: 17
Known assets: 0
Sponsor activity
Competitive footprint
Unique sponsors: 12
Top sponsors: Hansoh BioMedical R&D | University Health Network, Toronto | Nader Sanai
Tumor types: Advanced Solid Tumor | Osteosarcoma | Metastasis Castration Resistant Prostate Cancer(mCRPC)
Patent-density signal summary
Patent layer
Signal count: 1
Recent signals: 1
Top assignees: Zymeworks
Signal types: adc_composition
Scores and labels
Deterministic summary
Clinical crowding: 4/5 (High)
Clinical maturity: 1/5 (Phase 1 Only)
Patent density: 1/5 (Low)
Momentum: 3/5 (Rising)
Confidence: High
Limitations
Manual review still matters
This page summarizes public metadata patterns. It does not conclude patent scope, freedom to operate, clinical superiority, or commercial attractiveness.